Deventer, November 22, 2024 – 819 Capital Partners has acquired and invested in CiMaas, a biotech company dedicated to developing Natural Killer cell therapy to improve cancer treatment and patient outcomes.
Pioneering Immunotherapy Solutions for Advanced Cancer Treatment
Founded in 2015, CiMaas BV is a spin-off from Maastricht University and Maastricht University Medical Center+ (UM/Maastricht UMC+). CiMaas is transforming cancer treatment by developing innovative immunotherapies that harness the body’s immune system to address unmet needs in metastatic and late-stage cancers. Current therapies cure only 60% of patients in the Western world and often fail in advanced cases.
CiMaas focuses on safe, effective solutions that minimize side effects while enhancing quality of life. By integrating multiple components of the immune system, CiMaas aims to deliver more robust, lasting treatments—bringing new hope to patients.
For collaborations with partners, (non-) GMP-grade feeder cells are now also available. These make it possible to let Natural Killer expand sufficiently, so that sufficient numbers of these cells can be produced for both scientific research and treatment of patients. Furthermore, CiMaas aims to have clinical production ready for Natural Killer cells soon to start clinical research in collaboration with various partners.
Gerard Bos, CEO, CiMaas
“We are pleased to partner with 819 Capital Partners. This investment enables us to continue working on our ambitions: cure cancer patients by making Natural Killer cells a reality. Our commitment to advancing cell-therapy opportunities for cancer treatment remains as strong as ever, and we are very motivated to continue our work in this vital field now In the coming period, we will further strengthen our team with highly skilled professionals.”
Thomas Smit, director 819 Capital Partners
“We are delighted to welcome CiMaas to 819 Evergreen Fund I. Our investment in CiMaas perfectly aligns with our vision to accelerate the growth of cutting-edge ventures. CiMaas’ pioneering technology has great potential and could be a transformative breakthrough in cancer treatment in the future.”
About CiMaas
CiMaas focuses on the development of immunotherapies for specific types of cancer. The company specializes in creating innovative products based on immune system cells, and antibodies. It has created a platform technology using feeder cells for efficient expansion of NK cells. Founded in 2015, CiMaas BV is a spin-off from Maastricht University and Maastricht University Medical Center+ (UM/Maastricht UMC+). For more information: https://cimaas.com/
819 Capital Partners
819 Capital Partners is an investment firm managing multiple funds with targeted investment strategies. 819 Evergreen Fund takes minority stakes in early-stage deep-tech and med-tech startups, while 819 Private Equity Fund acquires controlling stakes in mature firms within the leisure, IT, and healthcare industries. The open-ended structure of their funds allows for long-term investments with flexible exit timelines. The firm focuses on sectors like healthcare, technology, and leisure, addressing societal challenges such as aging populations.
